April 2012

The Trials in Progress section supplies summaries of ongoing research in a broad range of cancer types.

US investigators have found that suicide rates in recent years have significantly increased in patients with oral cavity and oropharyngeal cancer.

Located in Tampa, Florida, Moffitt Cancer Center enjoys a reputation as one of the world's most sophisticated cancer centers.

Discussion with Andrew D. Zelenetz, MD, PhD, on a number of new therapies and interesting challenges regarding the treatment of patients with both Hodgkin and non- Hodgkin lymphoma.

Dutasteride may postpone disease progression in men with low-risk prostate cancer who have opted for an active surveillance strategy.

With the recent consideration of the 2010 Affordable Care Act by the US Supreme Court, the rising costs of healthcare have appeared, once again, on our radar screens.

Minimally invasive transoral robotic surgery, used alone or combined with adjuvant therapy, provides good functional and oncologic outcomes in patients with oropharyngeal squamous cell carcinoma.

Coronary artery disease and prostate cancer have been shown to share several modifiable and nonmodifiable risk factors including age, race, family history, and possibly diet.

A discussion with Pat Whitworth, Jr, MD, on how breast cancer treatment has evolved from a 'kitchen sink' approach with chemotherapy to a new paradigm that targets chemosensitivity.

Debu Tripathy, MD, from the University of Southern California Norris Comprehensive Cancer Center, was one of four co-chairs of the 2012 Miami Breast Cancer Conference.

The addition of thalidomide to chemoradiotherapy provides no survival benefit and increases toxicity in patients with unresectable stage III non-small cell lung cancer.

Monitoring bone health and ensuring adequate calcium and vitamin D intake in postmenopausal women who are taking exemestane for the primary prevention of breast cancer is essential.

Before the oncology treatment paradigm can move from a one-size-fits-all model to true personalized medicine, the medical establishment must find a cost-effective way to identify biomarkers.

Results of recent trials investigating novel therapies for chronic lymphocytic leukemia were discussed at the 16th Annual International Congress on Hematologic Malignancies.

The paradigm of "more energy is better" is not limited to space travel, and in fact is center stage in a growing debate in the field of radiation oncology.